Table 1.
Association between HRK methylation and clinicopathological variables in MDS patients.
| Characteristics |
HRK
Methylated (11)
|
HRK
Unmethylated (43)
|
P-value | ||
|---|---|---|---|---|---|
| Median (range) | n (%) | Median (range) | n (%) | ||
| Age (Years) | 59 (23-75) | 62.18 (38-90) | 0.525 | ||
|
Sex
Male Female |
- 4 (13.8%) 7(28%) |
- 25 (86.2%) 18 (72%) |
0.196 | ||
| WBC (×109/L) | 3.1(1.2-5) | 5.4 (1.5-1.38) | 0.00 | ||
| ANC (×109/L) | 1.3(0.29-3.2) | 3 (0.59-8.4) | 0.00 | ||
| Hb (g/L) | 9.58 (6.8-14.1) | 9.61 (5.6-14.8) | 0.963 | ||
| Platelets (×109/L) | 80.36 (30-141) | 149.6 (7-752) | 0.105 | ||
| SF (ng/ml) | 407.73 (134-690) | 380.89 (2.9-1600) | 0.805 | ||
| LDH (U/L) | 664.11 (385-1886) | 345 (99-1022) | 0.00 | ||
| LDH>400U/l LDH<400U/l |
10 (45.45%) 1 (3.1%) |
12 (54.54%) 31 (96.9%) |
0.00 | ||
|
BM Blast (%)
<5% >5% |
1 (2.56%) 10 (66.66%) |
38 (97.43%) 5 (33.33%) |
0.00 | ||
|
Karyotype(IPSS-R)
Very Good Good Intermediate Poor Very poor |
- 0 (0%) 4 (11.11%) 2 (25%) 2 (66.66%) 3 (100%) |
- 4 (100%) 32 (88.88%) 6 (75%) 1 (33.33%) 0 (0%) |
0.001 | ||
|
IPSS-R
Very low Low Int High Very high |
- 1 (5%) 1 (7.7%) 1 (12.5%) 1 (25%) 7 (77.77%) |
- 19 (95%) 12 (92.3%) 7 (87.5%) 3 (75%) 2 (22.22%) |
0.00 | ||
|
WHO classification
RA RT RCMD RAEB-1 RAEB-2 -5q |
- 1 (5%) 0 (0%) 0 (0%) 3 (75%) 7 (63.63%) 0 (0%) |
- 19(95%) 6 (100%) 10 (100%) 1 (25%) 4 (36.36%) 3 (100%) |
0.00 | ||
WBC: white blood cell count; ANC: absolute neutrophil count; Hb: hemoglobin; Plt, platelet; SF: serum ferritin; LDH: lactate dehydrogenase; IPSS-R: international prognostic scoring system (revised); WHO: world health organization; RA: refractory anemia; RT: refractory thrombocytopenia; RCMD: refractory anemia with multilineage dysplasia ; RAEB-1: refractory anemia with excess blasts-1; REAB-2: refractory anemia with excess blasts-2; -5q: MDS associated with isolated del (5q-).